Nyxoah (XBRU:NYXH) Debt-to-Revenue : 1.74 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nyxoah Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Nyxoah's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.22 Mil. Nyxoah's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €11.49 Mil. Nyxoah's annualized Revenue for the quarter that ended in Dec. 2023 was €7.30 Mil. Nyxoah's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 1.74.

Nyxoah Debt-to-Revenue Historical Data

The historical data trend for Nyxoah's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah Debt-to-Revenue Chart

Nyxoah Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

167.25

13.70

3.85

2.92

Nyxoah Quarterly Data
	Dec17	Dec18	Jun19	Dec19	Mar20	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial														2.27	7.14	2.88	3.32	1.74

Competitive Comparison of Nyxoah's Debt-to-Revenue

For the Medical Instruments & Supplies subindustry, Nyxoah's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyxoah's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nyxoah's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nyxoah's Debt-to-Revenue falls into.

Nyxoah Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Nyxoah's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.215	+	11.489)	/	4.348
	=	2.92

Nyxoah's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.215	+	11.489)	/	7.296
	=	1.74

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Nyxoah Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nyxoah's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyxoah (XBRU:NYXH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (XBRU:NYXH) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

NYXH:USA 5YI:Germany

Address

Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435

Website

https://www.nyxoah.com

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.